Encouraging patients to ask about the Shingrix vaccine
Nudging Patients to Increase Shingles Vaccination
NA · Geisinger Clinic · NCT06238726
This study is testing if sending different messages to patients over 50 can encourage them to ask about getting the Shingrix vaccine during their doctor visits.
Quick facts
| Phase | NA |
|---|---|
| Study type | Interventional |
| Enrollment | 50000 (estimated) |
| Ages | 50 Years and up |
| Sex | All |
| Sponsor | Geisinger Clinic (other) |
| Locations | 1 site (Danville, Pennsylvania) |
| Trial ID | NCT06238726 on ClinicalTrials.gov |
What this trial studies
This study aims to determine if sending messages to patients can increase the rate of Shingrix vaccinations by encouraging them to inquire about the vaccine during their primary care appointments. It will compare the effectiveness of different message versions that vary in content, including risk information and facts about shingles and the vaccine. The study will also assess the impact of the number of messages sent and whether cost information influences patient behavior. Participants will be patients aged 50 and older who have not yet received the Shingrix vaccine and have a scheduled appointment at a Geisinger clinic.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 50 and older who have not received any doses of the Shingrix vaccine and have a scheduled primary care appointment.
Not a fit: Patients who have already received the Shingrix vaccine or those who cannot be contacted through the study's communication methods will not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly increase Shingrix vaccination rates among older adults, reducing the incidence of shingles and its complications.
How similar studies have performed: Other studies have shown that targeted messaging can effectively increase vaccination rates, suggesting this approach may be promising.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 50+ * Has not received any doses of the Shingrix vaccine according to the Geisinger EHR * Has a non-acute in-person Geisinger primary care appointment in a department that stocks Shingrix scheduled with enough time to be randomized Exclusion Criteria: * Cannot be contacted via the communication modality being used in the study (e.g., patient portal, SMS), e.g., due to insufficient/missing contact information in the EHR or because they opted out * Patient does not have an approved insurance on file for Shingrix outreach for their appointment type or department * Appointment type or department not approved for outreach by Geisinger leadership at the time of outreach * While a separate flu vaccination nudge campaign is running (approximately from September through December, 2024), patients will be excluded if they have not received a flu shot in the 2024-25 flu season according to the EHR. Such patients will be eligible for inclusion again as soon as the flu vaccination campaign ends.
Where this trial is running
Danville, Pennsylvania
- Geisinger Clinic — Danville, Pennsylvania, United States (RECRUITING)
Study contacts
- Principal investigator: Christopher F Chabris, PhD — Geisinger Clinic
- Study coordinator: Amir Goren, PhD
- Email: agoren@geisinger.edu
- Phone: 570-214-3495
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Shingles, Vaccination Behavior, Behavior, Health